Fisher to invest Rs 100 cr in Cadila SEZ

The unit will be 100% export-oriented

Fisher Scientific International (FSI), a Fortune 500 company, will invest more than Rs 100 crore for a 100 per cent export-oriented unit in the Cadila-promoted special economic zone (SEZ) at Changodar near Ahmedabad. The company has already bought land for the unit, to be called Fisher Clinical.

To mark its entry into India, the US-based $5.6 billion manufacturer of lab equipment for drug research, acquired the Mumbai-based Ultrapure Scientifics recently.

After the acquisition, Ultrapure has been renamed Scientific Products (Indis) Pvt Ltd (SPIPL), and it has become FSI's 100 per cent subsidiary.

SPIPL will be operated as a marketing firm while Fisher Clinical will become 100 per cent export-oriented unit, sources said.

Fisher Clinical will produce consumable supplies for clinical applications, including drugs-of-abuse testing, specimen collection, veterinary and dairy testing and general packaging and storage in the SEZ. These products include leak-proof plastic vials and containers.

The company will target clinical and reference laboratories, critical-care hospital labs, industrial and pharmaceutical research, and the veterinary and dairy industries.

FSI provides products and services to the scientific-research community and clinical laboratories.

It serves pharmaceutical and biotech companies, colleges and universities, medical research institutions, hospitals, reference, quality-control, process-control and R&D labs across various industries.

Company also provides an unmatched suite of more than 6,00,000 products and services to its 3,50,000 customers worldwide.